Department of Production Animal Studies, Faculty of Veterinary Science, University of Pretoria, Pretoria, South Africa.
Department of Production Animal Studies, Faculty of Veterinary Science, University of Pretoria, Pretoria, South Africa; Next Generation Health Cluster, Council for Scientific and Industrial Research, Pretoria, South Africa.
Poult Sci. 2023 Oct;102(10):102953. doi: 10.1016/j.psj.2023.102953. Epub 2023 Jul 22.
Infectious bronchitis (IB) Gammacoronavirus causes a highly contagious respiratory disease in chickens that is listed by the World Organisation for Animal Health (WOAH). Its high mutation ability has resulted in numerous variants against which the commercially available live or recombinant vaccines singly offer limited protection. Agrobacterium-mediated transient expression in Nicotiana benthamiana (tobacco) plants was used here to produce a virus-like particle (VLP) vaccine expressing a modified full-length IBV spike (S) protein of a QX-like IB variant. In a challenge study with the homologous live IB QX-like virus, VLP-vaccinated birds produced S protein-specific antibodies comparable to those produced by live-vaccinated birds seroconverting with mean geometric titers of 6.8 and 7.2 log, respectively. The VLP-vaccinated birds had reduced oropharyngeal and cloacal viral shedding compared to an unvaccinated challenged control and were more protected against tracheal ciliostasis than the live-vaccinated birds. While the results appeared similar, plant-produced IB VLPs are safer, more affordable, easier to produce and update to antigenically match any emerging IB variant, making them a more suitable alternative to IBV control than live-attenuated vaccines.
传染性支气管炎(IB)γ冠状病毒可引起鸡的高度传染性呼吸道疾病,该疾病已被世界动物卫生组织(WOAH)列出。其高突变能力导致了许多变体,针对这些变体,市售的活疫苗或重组疫苗单独提供的保护作用有限。本研究采用根瘤农杆菌介导的瞬时表达在本氏烟(烟草)植物中表达一种改良的全长 IBV 刺突(S)蛋白的 QX 样 IB 变体的病毒样颗粒(VLP)疫苗。在与同源活 IB QX 样病毒的攻毒研究中,VLP 疫苗接种的鸟类产生的 S 蛋白特异性抗体与活疫苗接种的鸟类血清转化率相当,平均几何滴度分别为 6.8 和 7.2 log。与未接种攻毒对照相比,VLP 疫苗接种的鸟类口咽和泄殖腔的病毒脱落减少,并且比活疫苗接种的鸟类更能抵抗气管纤毛静止。虽然结果似乎相似,但植物生产的 IB VLP 更安全、更经济实惠、更容易生产和更新以匹配任何新出现的 IB 变体的抗原性,使其成为比活疫苗更适合 IBV 控制的替代方法。